Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, February 20, 2016

INFORMS Published: Fingolimod Fails in Primary Progressive MS

February 19, 2016

Full details of the INFORMS trial have confirmed that the multiple sclerosis (MS) drug fingolimod did not slow progression of disability or brain volume loss vs placebo in the primary progressive form of the disease.
The trial results have now been published online in The LancetJanuary 27, with lead author Fred Lublin, MD, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, New York. Top-line results were announced previously by Novartis.
In the Lancet paper, Professor Lublin and colleagues note that fingolimod did show an anti-inflammatory effect in the INFORMS trial, significantly reducing the numbers of gadolinium-enhancing and new T2 lesions on brain MRI. However, unlike the situation with fingolimod in relapsing-remitting MS, this had little effect on the process that leads to brain volume loss and disability progression in the primary-progressive MS population.
They conclude that: "The results of INFORMS suggest that anti-inflammatory strategies applied at present in relapse-onset multiple sclerosis are unlikely to be beneficial in primary progressive multiple sclerosis, and that novel approaches might be needed to treat patients with primary progressive multiple sclerosis.

MS Views and News 
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information 
by opting-in to our website: click here - thank you

No comments: